Tau Protein Pathology in Neurodegenerative Diseases

Tau is a microtubule-associated protein that stabilises cytoskeletal structures in neurons. In numerous neurodegenerative disorders, collectively termed tauopathies, tau undergoes aberrant post-translational modifications—most notably hyperphosphorylation—that reduce its affinity for microtubules and promote misfolding. Misfolded tau monomers assemble into oligomers and fibrils, forming neurofibrillary tangles and other inclusions that correlate with synaptic dysfunction, neuronal loss and clinical decline. These aggregates propagate through the brain in a prion-like manner, transferring pathology via extracellular vesicles or direct neuron-to-neuron transmission. Distinct tau isoforms and conformers underlie the diversity of clinical phenotypes, from Alzheimer’s disease with paired helical filaments to 4R-tau disorders such as corticobasal degeneration. Advances in structural biology have revealed conserved filament folds, while mass-spectrometric profiling has uncovered isoform- and modification-specific signatures. Translational efforts now focus on blocking aggregation, enhancing clearance and developing fluid-based biomarkers to distinguish tauopathies ante mortem. The global burden of dementia and Parkinsonian syndromes underscores the urgency of understanding tau pathology for the development of targeted diagnostics and therapies.

Research from Nature Portfolio

Recent studies have shown that assembled tau filaments in Alzheimer’s disease are sequestered within extracellular vesicles enriched in endo-lysosomal proteins. High-resolution cryo-electron microscopy and mass spectrometry revealed that truncated tau fragments form filaments tethered to the vesicle membrane by specific linker molecules, suggesting a selective packaging mechanism that may drive prion-like propagation and influence clearance pathways. Another investigation has delineated unique post-translational modification patterns on soluble tau from human brain tissue, distinguishing Alzheimer’s disease from primary tauopathies. By comparing aggregated and soluble tau, researchers identified ubiquitination and acetylation marks that are selective for particular disorders, offering candidate fluid biomarkers able to discriminate tauopathies in vivo and guiding precision-medicine approaches to diagnosis and therapeutic monitoring.

Tau Protein Pathology in Neurodegenerative Diseases publication trend

The graph below shows the total number of articles in tau protein pathology in neurodegenerative diseases across all publications each year (not limited to Nature Index journals).

Technical terms

Tauopathy: A neurodegenerative disorder characterised by abnormal tau aggregation and filament formation in the brain.

Hyperphosphorylation: Excessive addition of phosphate groups to tau, reducing its microtubule affinity and promoting misfolding.

Extracellular vesicles: Membrane-bound particles released by cells that mediate intercellular transfer of proteins, including pathogenic tau species.

Post-translational modification: Covalent modifications (e.g., phosphorylation, ubiquitination, acetylation) that regulate protein function and aggregation propensity.

Proteoform: A distinct molecular form of a protein arising from genetic variation, alternative splicing or post-translational modifications.

References

1. Neurodegenerative Disease Tauopathies. Annual Review of Pathology Mechanisms of Disease (2023).
2. Distinct Tau Prion Strains Propagate in Cells and Mice and Define Different Tauopathies. Neuron (2014).
3. Tau filaments from multiple cases of sporadic and inherited Alzheimer’s disease adopt a common fold. Acta Neuropathologica (2018).
4. Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau. Acta Neuropathologica (2015).
5. Tau filaments are tethered within brain extracellular vesicles in Alzheimer’s disease. Nature Neuroscience (2024).
6. Specific post-translational modifications of soluble tau protein distinguishes Alzheimer’s disease and primary tauopathies. Nature Communications (2023).
7. Co-opting templated aggregation to degrade pathogenic tau assemblies and improve motor function. Cell (2024).
8. Tau protein profiling in tauopathies: a human brain study. Molecular Neurodegeneration (2024).